HGS stock skyrockets on Glaxo deal talk

Talk is once again raging that GlaxoSmithKline is negotiating to buy Human Genome Sciences for some $4 billion. HGS, which makes an experimental lupus drug, saw its stock soar for the sixth straight day on rumors that Glaxo might make a $30-per-share-offer. Report

Suggested Articles

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.